<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35280925</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2162-2531</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>28</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular therapy. Nucleic acids</Title>
          <ISOAbbreviation>Mol Ther Nucleic Acids</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson's disease.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>15</EndPage>
          <MedlinePgn>1-15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtn.2022.02.007</ELocationID>
        <Abstract>
          <AbstractText>Parkinson's disease (PD) is caused by the loss of dopaminergic (DA) neurons in the substantia nigra (SN). Although PD pathogenesis is not fully understood, studies implicate perturbations in gene regulation, mitochondrial function, and neuronal activity. MicroRNAs (miRs) are small gene regulatory RNAs that inhibit diverse subsets of target mRNAs, and several studies have noted miR expression alterations in PD brains. For example, miR-181a is abundant in the brain and is increased in PD patient brain samples; however, the disease relevance of this remains unclear. Here, we show that miR-181 target mRNAs are broadly downregulated in aging and PD brains. To address whether the miR-181 family plays a role in PD pathogenesis, we generated adeno-associated viruses (AAVs) to overexpress and inhibit the miR-181 isoforms. After co-injection with AAV overexpressing alpha-synuclein (aSyn) into mouse SN (PD model), we found that moderate miR-181a/b overexpression exacerbated aSyn-induced DA neuronal loss, whereas miR-181 inhibition was neuroprotective relative to controls (GFP alone and/or scrambled RNA). Also, prolonged miR-181 overexpression in SN alone elicited measurable neurotoxicity that is coincident with an increased immune response. mRNA-seq analyses revealed that miR-181a/b inhibits genes involved in synaptic transmission, neurite outgrowth, and mitochondrial respiration, along with several genes having known protective roles and genetic links in PD.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stein</LastName>
            <ForeName>Colleen S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Iowa Neuroscience Institute, Fraternal Order of Eagles Diabetes Research Center, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McLendon</LastName>
            <ForeName>Jared M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Iowa Neuroscience Institute, Fraternal Order of Eagles Diabetes Research Center, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Witmer</LastName>
            <ForeName>Nathan H</ForeName>
            <Initials>NH</Initials>
            <AffiliationInfo>
              <Affiliation>Program in Molecular Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boudreau</LastName>
            <ForeName>Ryan L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Iowa Neuroscience Institute, Fraternal Order of Eagles Diabetes Research Center, Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Program in Molecular Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL148796</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Ther Nucleic Acids</MedlineTA>
        <NlmUniqueID>101581621</NlmUniqueID>
        <ISSNLinking>2162-2531</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AAV</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s disease</Keyword>
        <Keyword MajorTopicYN="N">aging</Keyword>
        <Keyword MajorTopicYN="N">antimiR</Keyword>
        <Keyword MajorTopicYN="N">gene therapy</Keyword>
        <Keyword MajorTopicYN="N">miR-181</Keyword>
        <Keyword MajorTopicYN="N">microRNAs</Keyword>
        <Keyword MajorTopicYN="N">neurodegeneration</Keyword>
        <Keyword MajorTopicYN="N">neuroprotection</Keyword>
        <Keyword MajorTopicYN="N">tough decoy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35280925</ArticleId>
        <ArticleId IdType="pmc">PMC8899134</ArticleId>
        <ArticleId IdType="doi">10.1016/j.omtn.2022.02.007</ArticleId>
        <ArticleId IdType="pii">S2162-2531(22)00035-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., et al.  alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14593171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koprich J.B., Johnston T.H., Reyes M.G., Sun X., Brotchie J.M. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol. Neurodegener. 2010;5:43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2984491</ArticleId>
            <ArticleId IdType="pubmed">21029459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp. Neurol. 2008;209:22–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2262051</ArticleId>
            <ArticleId IdType="pubmed">17949715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Decressac M., Mattsson B., Lundblad M., Weikop P., Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 2012;45:939–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22182688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakur P., Breger L.S., Lundblad M., Wan O.W., Mattsson B., Luk K.C., Lee V.M.Y., Trojanowski J.Q., Bjorklund A. Modeling Parkinson's disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain. Proc. Natl. Acad. Sci. United States America. 2017;114:E8284–E8293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5625925</ArticleId>
            <ArticleId IdType="pubmed">28900002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgos K., Malenica I., Metpally R., Courtright A., Rakela B., Beach T., Shill H., Adler C., Sabbagh M., Villa S., et al.  Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS one. 2014;9:e94839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4010405</ArticleId>
            <ArticleId IdType="pubmed">24797360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briggs C.E., Wang Y., Kong B., Woo T.U., Iyer L.K., Sonntag K.C. Midbrain dopamine neurons in Parkinson's disease exhibit a dysregulated miRNA and target-gene network. Brain Res. 2015;1618:111–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4522231</ArticleId>
            <ArticleId IdType="pubmed">26047984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Rooij E., Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 2014;6:851–864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4119351</ArticleId>
            <ArticleId IdType="pubmed">24935956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupaimoole R., Slack F.J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017;16:203–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28209991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao Y.S., Mott N.N., Wang Y., Chung W.C., Pak T.R. MicroRNAs in the aging female brain: a putative mechanism for age-specific estrogen effects. Endocrinology. 2013;154:2795–2806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3713211</ArticleId>
            <ArticleId IdType="pubmed">23720423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cel. 2007;27:91–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3800283</ArticleId>
            <ArticleId IdType="pubmed">17612493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegarty S.V., Sullivan A.M., O'Keeffe G.W. Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson's disease. Neuronal Signal. 2018;2:NS20170181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7371012</ArticleId>
            <ArticleId IdType="pubmed">32714583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saba R., Storchel P.H., Aksoy-Aksel A., Kepura F., Lippi G., Plant T.D., Schratt G.M. Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol. Cell. Biol. 2012;32:619–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3266602</ArticleId>
            <ArticleId IdType="pubmed">22144581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He M., Liu Y., Wang X., Zhang M.Q., Hannon G.J., Huang Z.J. Cell-type-based analysis of microRNA profiles in the mouse brain. Neuron. 2012;73:35–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3270494</ArticleId>
            <ArticleId IdType="pubmed">22243745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boudreau R.L., Jiang P., Gilmore B.L., Spengler R.M., Tirabassi R., Nelson J.A., Ross C.A., Xing Y., Davidson B.L. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron. 2014;81:294–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4108341</ArticleId>
            <ArticleId IdType="pubmed">24389009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghorbani S., Talebi F., Ghasemi S., Jahanbazi Jahan Abad A., Vojgani M., Noorbakhsh F. miR-181 interacts with signaling adaptor molecule DENN/MADD and enhances TNF-induced cell death. PLoS one. 2017;12:e0174368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5360339</ArticleId>
            <ArticleId IdType="pubmed">28323882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng M., Liu L., Lao Y., Liao W., Liao M., Luo X., Wu J., Xie W., Zhang Y., Xu N. MicroRNA-181a suppresses parkin-mediated mitophagy and sensitizes neuroblastoma cells to mitochondrial uncoupler-induced apoptosis. Oncotarget. 2016;7:42274–42287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5173134</ArticleId>
            <ArticleId IdType="pubmed">27281615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Indrieri A., Carrella S., Romano A., Spaziano A., Marrocco E., Fernandez-Vizarra E., Barbato S., Pizzo M., Ezhova Y., Golia F.M., et al.  miR-181a/b downregulation exerts a protective action on mitochondrial disease models. EMBO Mol. Med. 2019;11:e8734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505685</ArticleId>
            <ArticleId IdType="pubmed">30979712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouyang Y.B., Lu Y., Yue S., Xu L.J., Xiong X.X., White R.E., Sun X., Giffard R.G. miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. Neurobiol. Dis. 2012;45:555–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3251314</ArticleId>
            <ArticleId IdType="pubmed">21983159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spengler R.M., Zhang X., Cheng C., McLendon J.M., Skeie J.M., Johnson F.L., Davidson B.L., Boudreau R.L. Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP. Nucleic Acids Res. 2016;44:7120–7131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5009757</ArticleId>
            <ArticleId IdType="pubmed">27418678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kugler S., Lingor P., Scholl U., Zolotukhin S., Bahr M. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology. 2003;311:89–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12832206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haraguchi T., Ozaki Y., Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009;37:e43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2665227</ArticleId>
            <ArticleId IdType="pubmed">19223327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3056408</ArticleId>
            <ArticleId IdType="pubmed">21040844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert K., Voutilainen M.H., Domanskyi A., Airavaara M. AAV vector-mediated gene delivery to substantia nigra dopamine neurons: implications for gene therapy and disease models. Genes (Basel) 2017;8:63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5333052</ArticleId>
            <ArticleId IdType="pubmed">28208742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J., Bardes E.E., Aronow B.J., Jegga A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37:W305–W311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2703978</ArticleId>
            <ArticleId IdType="pubmed">19465376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore M.J., Scheel T.K., Luna J.M., Park C.Y., Fak J.J., Nishiuchi E., Rice C.M., Darnell R.B. miRNA-target chimeras reveal miRNA 3'-end pairing as a major determinant of Argonaute target specificity. Nat. Commun. 2015;6:8864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4674787</ArticleId>
            <ArticleId IdType="pubmed">26602609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabresi P., Picconi B., Tozzi A., Ghiglieri V., Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat. Neurosci. 2014;17:1022–1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25065439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ford C.P. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4108583</ArticleId>
            <ArticleId IdType="pubmed">24463000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou W., Ma D., Sun A.X., Tran H.D., Ma D.L., Singh B.K., Zhou J., Zhang J., Wang D., Zhao Y., et al.  PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. Hum. Mol. Genet. 2019;28:1100–1116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6423417</ArticleId>
            <ArticleId IdType="pubmed">30496485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., et al.  A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329–2345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4107737</ArticleId>
            <ArticleId IdType="pubmed">24934289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funayama M., Ohe K., Amo T., Furuya N., Yamaguchi J., Saiki S., Li Y., Ogaki K., Ando M., Yoshino H., et al.  CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol. 2015;14:274–282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25662902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korecka J., Schouten M., Eggers R., Ulusoy A., Bossers K., Verhaagen J. Comparison of AAV serotypes for gene delivery to dopaminergic neurons in the substantia nigra. Viral Gene Ther. 2011;2:205–224.</Citation>
        </Reference>
        <Reference>
          <Citation>Ulusoy A., Decressac M., Kirik D., Bjorklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res. 2010;184:89–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20887871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodore S., Cao S., McLean P.J., Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2008;67:1149–1158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2753200</ArticleId>
            <ArticleId IdType="pubmed">19018246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveras-Salva M., Van der Perren A., Casadei N., Stroobants S., Nuber S., D'Hooge R., Van den Haute C., Baekelandt V. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol. Neurodegener. 2013;8:44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4222878</ArticleId>
            <ArticleId IdType="pubmed">24267638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren L., Zhu R., Li X. Silencing miR-181a produces neuroprotection against hippocampus neuron cell apoptosis post-status epilepticus in a rat model and in children with temporal lobe epilepsy. Genet. Mol. Res. : GMR. 2016;15:15017798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26910006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horst C.H., Titze-de-Almeida R., Titze-de-Almeida S.S. The involvement of Eag1 potassium channels and miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells. Mol. Med. Rep. 2017;15:1479–1488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5364983</ArticleId>
            <ArticleId IdType="pubmed">28259991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhuri A.D., Kabaria S., Choi D.C., Mouradian M.M., Junn E. MicroRNA-7 promotes glycolysis to protect against 1-methyl-4-phenylpyridinium-induced cell death. J. Biol. Chem. 2015;290:12425–12434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4424371</ArticleId>
            <ArticleId IdType="pubmed">25814668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z.Y., Chen B., Zhang J.P., Ma Y.Y. Up-regulation of autophagy-related gene 5 (ATG5) protects dopaminergic neurons in a zebrafish model of Parkinson's disease. J. Biol. Chem. 2017;292:18062–18074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5672032</ArticleId>
            <ArticleId IdType="pubmed">28928221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlsson T., Schindler F.R., Hollerhage M., Depboylu C., Arias-Carrion O., Schnurrbusch S., Rosler T.W., Wozny W., Schwall G.P., Groebe K., et al.  Systemic administration of neuregulin-1beta1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2011;117:1066–1074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21517849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyllborg D., Ahmed M., Toledo E.M., Theofilopoulos S., Yang S., Ffrench-Constant C., Arenas E. The matricellular protein R-Spondin 2 promotes midbrain dopaminergic neurogenesis and differentiation. Stem Cell Rep. 2018;11:651–664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6135723</ArticleId>
            <ArticleId IdType="pubmed">30146491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegarty S.V., Sullivan A.M., O'Keeffe G.W. BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons. Mol. Cell Neurosci. 2013;56:263–271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23831389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han D., Dong X., Zheng D., Nao J. MiR-124 and the underlying therapeutic promise of neurodegenerative disorders. Front Pharmacol. 2019;10:1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6978711</ArticleId>
            <ArticleId IdType="pubmed">32009959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao M.W., Yang P., Zhao L.L. Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181/SIRT1/PGC-1alpha/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells: implication for association between chlorpyrifos and Parkinson's disease. Environ. Toxicol. 2019;34:699–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30835941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu C., Shen J., Zhang F., Chen J. MicroRNA-181a knockdown protects HepaRG cells from Dichlorvos-induced oxidative stress and apoptosis. Int. J. Clin. Exp. Pathol. 2017;10:10883–10891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6965843</ArticleId>
            <ArticleId IdType="pubmed">31966431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Zhou S., Ding X., Zhu G., Guo J. Effect of triazophos, fipronil and their mixture on miRNA expression in adult zebrafish. J. Environ. Sci. Health B. 2010;45:648–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20818518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paxinos G., Franklin K.B.J.  San Diego: Academic Press; 2001. The Mouse Brain in Stereotaxic Coordinates.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee B.R., Kamitani T. Improved immunodetection of endogenous alpha-synuclein. PLoS one. 2011;6:e23939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3158774</ArticleId>
            <ArticleId IdType="pubmed">21886844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray N.L., Pimentel H., Melsted P., Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 2016;34:525–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27043002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pimentel H., Bray N.L., Puente S., Melsted P., Pachter L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat. Methods. 2017;14:687–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28581496</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
